Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon. Pediatr Blood Cancer 2012 Nov;59(5):934-8 PMID: 22648868 PMCID: PMC3528889

Pubmed ID

22648868

Abstract

Propranolol is a non-selective beta-adrenergic antagonist successfully used in a case of kaposiform hemangioendothelioma (KHE) associated with Kasabach-Merritt phenomenon (KMP). We report 11 patients treated with propranolol for KHE and the related variant tufted angioma (TA), six of whom also had KMP. The varied responses to treatment, with only 36% responding in our series, demonstrate the need for further study of this medication before routine use for these indications.

Author List

Chiu YE, Drolet BA, Blei F, Carcao M, Fangusaro J, Kelly ME, Krol A, Lofgren S, Mancini AJ, Metry DW, Recht M, Silverman RA, Tom WL, Pope E

Authors

Yvonne E. Chiu MD Associate Professor in the Dermatology department at Medical College of Wisconsin
Beth A. Drolet MD Professor in the Dermatology department at Medical College of Wisconsin




Scopus

2-s2.0-84866169497   81 Citations

MESH terms used to index this publication - Major topics in bold

Adrenergic beta-Antagonists
Child, Preschool
Female
Hemangioendothelioma
Hemangioma
Humans
Infant
Infant, Newborn
Kasabach-Merritt Syndrome
Male
Propranolol
Sarcoma, Kaposi
Skin Neoplasms
jenkins-FCD Prod-300 626508253d14e4184314fb9f66322a03a5906796